Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?


Creative Commons License

YONTAR O. C. , YILMAZ M. B. , YALTA K., TANDOĞAN İ.

ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY, vol.10, no.4, pp.310-316, 2010 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 4
  • Publication Date: 2010
  • Doi Number: 10.5152/akd.2010.088
  • Title of Journal : ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY
  • Page Numbers: pp.310-316

Abstract

Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosimendan does not increase cellular calcium intake, so that, does not cause intracellular calcium overload and related arrhythmias. Atrial fibrillation (AF) was shown to be an independent risk factor for mortality and morbidity in large heart failure (HF) trials. Heart failure induces AF, AF aggravates HF and therefore they generally coexist. We conducted a study to investigate if there is any differential effect of Levosimendan in HF patients with chronic AF and without AF.